多肽组学技术在体液生物标志物中的研究进展  

Recent Advances in Peptidomics of Body Fluid Biomarkers

作　　者：郑琬琳 万磊磊 李水明[1,2,3] 洪晓榆 王勇 ZHENG Wan-lin;WAN Lei-lei;LI Shui-ming;HONG Xiao-yu;WANG Yong(Brain Disease and Big Data Research Institute,Shenzhen Key Laboratory of Marine Bioresources and Ecology,College of Life Sciences and Oceanography,Shenzhen University,Shenzhen 518055,China;Shenzhen Bay Laboratory,Shenzhen 518055,China;Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions,Shenzhen 518055,China)

机构地区：[1]深圳大学生命科学学院,深圳市海洋生物资源与生态环境重点实验室,深圳市脑病和大数据研究所,广东深圳518055 [2]深圳湾实验室,广东深圳518055 [3]深圳-香港脑科学创新研究院,广东深圳518055

出　　处：《质谱学报》2021年第5期926-941,I0010,共17页Journal of Chinese Mass Spectrometry Society

基　　金：深圳市基础研究计划(JCYJ20170818142154551,JCYJ20200109110001818);深港脑科学创新研究院(2021SHIBS0003)。

摘　　要：多肽组学是蛋白质组学技术的延伸,理论上是指器官、组织、细胞和体液中分子质量小于10 ku的全部内源性多肽。体液多肽组包含了丰富的人体病理和生理信息,自2000年提出生物标记物研究以来,引起了研究者的广泛关注。本文对多肽组学的研究方法和3种体液多肽组生物标志物的发展和应用进行总结,提出多肽组的宽泛性,探讨利用肽段分子质量作为标记物的缺点,指出在多肽组分析的各个步骤都可能引入一定的不确定性。Peptidomics is an extension of proteomics.The target of peptidomicsis endogenous peptides with molecular weight less than 10 ku in organs,tissues,cells and body fluids.Body fluid peptides contain abundant pathological and physiological information of human.The studies of body fluid peptides as biomarkers had attracted tremendous attentions since they were proposed in 2000.This review covered the research methods of peptidomics and the development and application of three kinds of body fluid peptidome biomarkers,which pointed out the versatility of peptidomics.The disadvantages of using peptide molecular weight as biomarkers were also discussed.It indicated that some uncertainty might be introduced in each step of peptide analysis.

关 键 词：质谱 体液 多肽组 生物标记物 

分 类 号：O657.63[理学—分析化学]